


Mehrosh Pervaiz, Xavier Lucas, Lucas Paetow & Stefan Günther

Pharmaceutical Bioinformatics, Institute of Pharmaceutical Sciences,
Albert-Ludwigs-Universität Freiburg, 79104 Freiburg, Germany
mehrosh.pervaiz@pharmazie.uni-freiburg.de

Fragment-based virtual screening

Fragment-based virtual screening (FBVS) utilizes low molecular weight (MW<300) compounds to target subpockets within a protein's binding site [1]. The identified fragments are generally weak binders which can be combined or optimized to produce high affinity binders. Compared to ligand-based virtual screening, FBVS allows for screening of a much larger chemical space by using a smaller library [2].



Bromodomains

Bromodomains are emerging epigenetic targets in various types of cancer [3]. They recognize ϵ -N-acetylated lysine residues (K_{ac}) on the unstructured histone tails. The K_{ac} binding site of most bromodomains features a conserved asparagine residue responsible for substrate recognition [4]. Conversely, some bromodomains such as BRWD1, PHIP, and BRWD3 have a threonine residue in the same position (Figures 1 & 2). This threonine could act both as a hydrogen-bond donor and acceptor and is a good starting point for the identification of selective inhibitors. In this project we target BRWD1(2) using the FBVS approach.

	81	82	92	97	140
BRD4_1	F A W	P F Q Q P V D A V K	L N L P D Y Y K	I Y N	K
CREBBP	P E S	L P F R Q P V D P Q L L	G I P D Y F D	L Y N	R
EP300	P E S	L P F R Q P V D P Q L L	G I P D Y F D	L Y N	R
FALZ	M A W	P F L E P V D P N	- D A P D Y Y G	Y Y N	P
CECR2	D S W	P F L E P V D E S	- Y A P N Y Y Q	K Y N	G
GCN5L2	S A W	P F M E P V K K S	- E A P D Y Y E	E Y N	P
BRPF1A	T G N	I F S E P V P L S	- E V P D Y L D	K Y N	A
PHIP_2	D S E	P F R Q P V D L L E Y	- P D Y R D	A Y T P S	
BRWD1_2	D S E	P F R Q P V D L V E Y	- P D Y R D	A Y T P S	
BRWD3_2	E G E S S E S V V	P E R Q - Q D S S L S	- E D Y Q D	A Y T S N	

Figure 1. Multiple sequence alignment of selected bromodomains. The sequence of BRWD1(2) and residues involved in ligand recognition are highlighted.





Figure 2. Superposition of K_{ac} binding sites of BRD4(1) (PDB: 3UVW) and BRWD1(2) (PDB: 3Q2E). The acetylated lysine residue (shown in blue) is engaged in a hydrogen-bond with the conserved asparagine of BRD4(1).

Purchasable space of fragments

Commercially available compounds were collected and filtered using an automated workflow designed within the ChemicalToolBoX [6, 7]. Fragments were selected using the Rule of Three [1].



Druggability and chirality analysis

We have recently shown that low-druggability binding sites can be addressed with chiral molecules [5]. To get insight into the chirality demands of BRDs, we have analyzed the druggability of their recognition site. The results suggest that BRWD1(2) binds preferably chiral molecules.




Figure 3. Druggability analysis of several BRDs. Historical accessibility of the targets and their expected chirality demands are indicated. The average druggability value for difficult targets (0.871) is indicated as a dashed line.

Future prospects

- Identification of putative binding fragments of BRWD1(2)
- Experimental validation of identified fragments
- Co-crystallization of fragments with the target
- Structure-based fragment growing and ligand optimization
- Preliminary cellular assays

Collaborations

Biochemistry (experimental validation, X-ray crystallography):
Martin Hügle
Dr. Daniel Wohlwend
Prof. Dr. Oliver Einsle
Chemistry (organic synthesis):
Dr. Dmytro Ostrovskiy
Prof. Dr. Bernhard Breit
Chemical epigenetics (cellular assays):
Prof. Dr. Manfred Jung

Acknowledgments and Funding

JUNIOR RESEARCH GROUP PROGRAMME

DFG Deutsche Forschungsgemeinschaft




Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg

Black Forest Grid

bwGRiD

Screening workflow



References

1. Murray C.W., Rees D.C. (2009). The rise of fragment-based drug discovery. *Nature Chem.* 1:187-192.
2. Congreve M., Carr R., Murray C., Jhoti H. (2003). A 'Rule of Three' for fragment-based lead discovery? *Drug Discov Today.* 8(19):876-77.
3. Müller S., Fillippakopoulos P., Knapp S. (2011). Bromodomains as therapeutic targets. *Expert Rev Mol Med.* 13:e29.
4. Owen D.J., Ornaghi P., Yang J.C., Evans P.R., Ballario P., Neuhaus D., Filetici P., Travers A.A. (2000). The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gen5p. *EMBO J.* 19(22):6141-9.
5. Lucas X., Günther S. Using chiral molecules to address low-druggability recognition sites; (submitted).
6. Grüning B.A., Lucas X., Von Kuster G., Patel H., Chbeib M., Bleher S., Telukunta K.K., Merfort I., Günther S. ChemicalToolBoX, a new Galaxy for cheminformatics; (submitted); <http://www.ctb.phar.aceutical-bioinformatics.org>.
7. Lucas X., Günther S. Insights from the purchasable chemical space: the role of complexity in library design; (under revision).